VaXenta currently owns proprietary technology known as XenUvaX, which is an immunotherapy for cancer which directly inhibits cancer tumor growth. Additionally, XenUvaX can be used synergistically with current cancer immune stimulants, however unlike invasive treatments such as surgery and chemotherapy, XenUvaX is tailored to the specific needs the patient. VaXenta’s primary objective is to strategically commercialize intellectual properties associated with the XenUvaX cancer vaccine. VaXenta is focused on development and regulatory work for clinical introduction of XenUvaX into the U.S. clinical trial process for the treatment of Melanoma, strategically utilizing the FDA fast-track process of approval for cancer therapies. Additionally, VaXenta strongly believes that the XenUvaX vaccine will be applicable for all solid tumors, and in the future VaXenta intends on expanding the indications for its technology to other forms of cancer such as breast, prostate, bladder, and ovarian cancer.